Contract Deobligations Alert — June 23, 2026

Analogic Corp secured a competitive, firm-fixed-price delivery order for full-sized CT systems, indicating strong market position in airport security technology. The 11-year performance period provides long-term revenue visibility, and the full-and-open competition suggests no set-aside advantage.

Despite the large ceiling, only 2% of the contract value has been funded, indicating early-stage milestone payments. The company's small, foreign-owned, self-certified small disadvantaged business status raises scalability and investor confidence concerns.

The cost-plus-fixed-fee delivery order for NIAID VRC research ends in August 2024, with only $4.3 million in options remaining. This creates a near-term catalyst for a re-compete or follow-on award, which could affect Leidos' health R&D revenue stream.

START2 GROUP's $141.3M BARDA contract has only $2.8M outlayed (2% of total), with a 7.5-year performance period. The small, foreign-owned company may struggle to scale R&D operations, risking milestone delays or contract termination.

Two of three contracts (63% of total value) are from HHS agencies (BARDA and NIH), creating civilian health sector concentration. Any NIH or BARDA budget cuts or policy shifts could impact both START2 GROUP and Leidos Biomedical Research.

Analogic Corp's $138.3M TSA CT system contract was awarded under full and open competition, leaving it vulnerable to competitor protests or new entrants in the airport security CT market. The firm-fixed-price structure also carries execution risk if costs overrun.

Analogic Corp's $138.3M TSA delivery order, with $499.7M in potential value through 2033, positions the company to capture additional option exercises as TSA expands full-sized CT deployment. The competitive win signals strong technology moat in airport security.

START2 GROUP's $141.3M BARDA contract for biotechnology R&D, though early-stage, aligns with sustained federal biodefense spending. If the company executes milestones successfully, it could secure follow-on awards or option exercises, driving revenue growth from near-zero base.

Leidos Biomedical Research's $121.5M NIH contract expiration in August 2024 creates a re-compete opportunity. As a large, established contractor, Leidos is well-positioned to win a follow-on award, potentially at higher value if NIAID vaccine research funding increases.

Two of three contracts ($262.8M total) are from HHS agencies (BARDA and NIH), demonstrating continued investment in biodefense and health research. The START2 GROUP contract (biotechnology R&D) and Leidos Biomedical Research contract (vaccine research) both align with stable or growing federal health priorities.

Analogic Corp's $138.3M TSA delivery order for full-sized CT systems, with $499.7M potential value through 2033, reflects sustained federal investment in advanced checkpoint screening. The competitive win underscores Analogic's technology leadership in computed tomography for security.

{"entity"=>"Analogic Corp", "reason"=>"Won $138.3M TSA CT system delivery order with $499.7M potential; competitive win signals market strength", "trigger"=>"Option exercises on the IDIQ; TSA budget announcements for checkpoint CT systems; competitor protests"}

{"entity"=>"START2 GROUP, INC.", "reason"=>"Large $141.3M BARDA contract with only $2.8M outlayed; high execution risk and small-cap volatility", "trigger"=>"Quarterly outlayed amount updates; milestone achievement announcements; company financial filings"}

{"entity"=>"Leidos Holdings, Inc.", "reason"=>"$121.5M NIH contract expires August 2024; re-compete outcome will impact health R&D revenue stream", "trigger"=>"Re-compete solicitation release; NIH budget allocation for NIAID VRC; contract award announcement"}